Stay up-to-date with stories, interviews, event information and the latest announcements from your favorite travel brands. Find the latest hotspots and those 'never been done before' …

May 19, 2021 · X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here's what you need to know.

Operator of a biotechnology company intended to develop vaccines against pathogens acquired by a mucosal infection.

Aug 14, 2023 · Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D …

May 18, 2021 · An inside look at preclinical stage biotech, X-VAX, which is preparing to engage the FDA with data on an HSV vaccine candidate that could have therapeutic impact on a virus …

Jul 21, 2021 · PALM BEACH GARDENS, Fla., July 21, 2021 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX ®), a biotechnology company developing vaccines based on a new approach that …

JUPITER, Fla., July 23, 2019 /PRNewswire/ -- X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the …

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, …

Jul 23, 2019 · X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it …

Oct 3, 2019 · Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected …